Alz-Dementia Korea

Alz-Dementia Korea Co. is a biotechnology company based in South Korea that specializes in the discovery and development of innovative therapeutics and diagnostics for neurodegenerative disorders. The company’s research programs focus on multiple pathological hallmarks of Alzheimer's and Parkinson's diseases, including oxidative stress, neuroinflammation, and synaptic dysfunction. Their pre-clinical pipeline includes small molecules such as xanthurenic acid, an mGluR2/3 agonist, and N-methyl-(2S, 4R)-trans-4-hydroxy-L-proline (NMP), alongside peptide-based vaccines targeting alpha-synuclein. Alz-Dementia Korea is also advancing a proprietary microRNA-based diagnostic platform designed for the early detection and monitoring of cognitive impairment. The company maintains close academic ties with Gyeongsang National University to facilitate the translation of basic research into clinical candidates.